Notícias

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.

AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol

AbCellera Biologics Inc (ABCL) progresses its lead program into Phase II, despite reporting a net loss and increased R&D expenses.

AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl

Tryn Stimart: Thank you for joining us for AbCellera Biologics Inc.'s First Quarter 2026 Earnings Call. Doctor Carl L. Hansen, AbCellera Biologics Inc.'s President and CEO, Doctor Sarah Noonberg, AbCellera Biologics Inc.'s Chief Medical Officer, and Andrew Booth, AbCellera Biologics Inc.'s Chief Financial Officer, are speaking on today's call.